Locations:
SearchSustained success requires a cultural shift
Cleveland Clinic Cancer Center has made reducing the time from cancer diagnosis to treatment initiation a top priority. In four years, the multidisciplinary effort has decreased wait times by a remarkable 33%. Some patients are now able to begin chemotherapy or other treatment less than a week after their initial visit.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
How did this happen? As Cleveland Clinic Taussig Cancer Institute Chairman Brian J. Bolwell, MD, FACP, and Department of Hematology and Medical Oncology Chairman Jame Abraham, MD, FACP, explain in their new ASCO Post column, cutting time to treat required a change in institutional mindset, addressing a myriad of potential process bottlenecks, and a commitment to treat every patient like a family member.
Like many comprehensive cancer centers, at Cleveland Clinic it is a priority to get patients in quickly for an initial consultation. Our average time to see a patient with a new diagnosis of cancer is less than 7 days. In many cases, we are able to get these new patients in just days later to begin treatment as well. How can we make this the standard for every patient? Over the past 3 years, we have experimented with this idea and reduced the average time to treatment by 33%, with the largest cancer programs (breast, colorectal, and lung) showing the greatest improvement in time to treatment.
To make this happen, we started at the top. Buy-in from leadership across all specialties was important, as it set the tone for the entire enterprise. As cancer program leaders and teams intensely focused on improving time to treatment, we examined hundreds of operational opportunities across all disciplines and worked together to create efficiencies, from coordinating clinic visits for patients to aligning OR times for breast surgeons and plastic surgeons. As the results of our improvements became clear, our caregivers started to understand the driving force. It wasn’t about the data; it was about improving care for our patients.
Read the full ASCO Post column by Drs. Bolwell and Abraham here.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients